Plasma homocysteine levels and risk of Alzheimer disease

J. A. Luchsinger, M. X. Tang, S. Shea, J. Miller, Ralph Green, Richard Mayeux

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

Objective: To explore the association between high homocysteine levels and risk of Alzheimer disease (AD) in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Methods: The authors obtained fasting plasma samples in 909 elderly subjects chosen at random from a cohort of Medicare recipients; there was longitudinal data in 679 subjects without dementia at baseline who were followed for 3,206 person-years. Prevalent and incident dementia and its subtypes were diagnosed using standard methods. Results: There were 128 persons with prevalent AD and 109 with incident AD in 3,206 person-years of follow-up. The adjusted OR of prevalent AD for the highest quartile of homocysteine compared to the lowest was 1.3 (95% CI = 0.7, 2.3; p for trend = 0.25). In longitudinal analyses, the authors found that the adjusted hazard ratio of AD for the highest quartile of homocysteine was 1.4 (95% CI = 0.8, 2.4; p for trend = 0.31). The authors also found that high homocysteine levels were not related to a decline in memory scores over time. Age was a significant confounder in all the analyses. The study had 80% power to detect a hazard ratio of 1.3 in the longitudinal analyses. Conclusion: High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time.

Original languageEnglish (US)
Pages (from-to)1972-1976
Number of pages5
JournalNeurology
Volume62
Issue number11
StatePublished - Jun 8 2004

Fingerprint

Homocysteine
Alzheimer Disease
Dementia
Medicare
Fasting

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Luchsinger, J. A., Tang, M. X., Shea, S., Miller, J., Green, R., & Mayeux, R. (2004). Plasma homocysteine levels and risk of Alzheimer disease. Neurology, 62(11), 1972-1976.

Plasma homocysteine levels and risk of Alzheimer disease. / Luchsinger, J. A.; Tang, M. X.; Shea, S.; Miller, J.; Green, Ralph; Mayeux, Richard.

In: Neurology, Vol. 62, No. 11, 08.06.2004, p. 1972-1976.

Research output: Contribution to journalArticle

Luchsinger, JA, Tang, MX, Shea, S, Miller, J, Green, R & Mayeux, R 2004, 'Plasma homocysteine levels and risk of Alzheimer disease', Neurology, vol. 62, no. 11, pp. 1972-1976.
Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R. Plasma homocysteine levels and risk of Alzheimer disease. Neurology. 2004 Jun 8;62(11):1972-1976.
Luchsinger, J. A. ; Tang, M. X. ; Shea, S. ; Miller, J. ; Green, Ralph ; Mayeux, Richard. / Plasma homocysteine levels and risk of Alzheimer disease. In: Neurology. 2004 ; Vol. 62, No. 11. pp. 1972-1976.
@article{64b4850d27b149da9e5f0cafad774f32,
title = "Plasma homocysteine levels and risk of Alzheimer disease",
abstract = "Objective: To explore the association between high homocysteine levels and risk of Alzheimer disease (AD) in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Methods: The authors obtained fasting plasma samples in 909 elderly subjects chosen at random from a cohort of Medicare recipients; there was longitudinal data in 679 subjects without dementia at baseline who were followed for 3,206 person-years. Prevalent and incident dementia and its subtypes were diagnosed using standard methods. Results: There were 128 persons with prevalent AD and 109 with incident AD in 3,206 person-years of follow-up. The adjusted OR of prevalent AD for the highest quartile of homocysteine compared to the lowest was 1.3 (95{\%} CI = 0.7, 2.3; p for trend = 0.25). In longitudinal analyses, the authors found that the adjusted hazard ratio of AD for the highest quartile of homocysteine was 1.4 (95{\%} CI = 0.8, 2.4; p for trend = 0.31). The authors also found that high homocysteine levels were not related to a decline in memory scores over time. Age was a significant confounder in all the analyses. The study had 80{\%} power to detect a hazard ratio of 1.3 in the longitudinal analyses. Conclusion: High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time.",
author = "Luchsinger, {J. A.} and Tang, {M. X.} and S. Shea and J. Miller and Ralph Green and Richard Mayeux",
year = "2004",
month = "6",
day = "8",
language = "English (US)",
volume = "62",
pages = "1972--1976",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Plasma homocysteine levels and risk of Alzheimer disease

AU - Luchsinger, J. A.

AU - Tang, M. X.

AU - Shea, S.

AU - Miller, J.

AU - Green, Ralph

AU - Mayeux, Richard

PY - 2004/6/8

Y1 - 2004/6/8

N2 - Objective: To explore the association between high homocysteine levels and risk of Alzheimer disease (AD) in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Methods: The authors obtained fasting plasma samples in 909 elderly subjects chosen at random from a cohort of Medicare recipients; there was longitudinal data in 679 subjects without dementia at baseline who were followed for 3,206 person-years. Prevalent and incident dementia and its subtypes were diagnosed using standard methods. Results: There were 128 persons with prevalent AD and 109 with incident AD in 3,206 person-years of follow-up. The adjusted OR of prevalent AD for the highest quartile of homocysteine compared to the lowest was 1.3 (95% CI = 0.7, 2.3; p for trend = 0.25). In longitudinal analyses, the authors found that the adjusted hazard ratio of AD for the highest quartile of homocysteine was 1.4 (95% CI = 0.8, 2.4; p for trend = 0.31). The authors also found that high homocysteine levels were not related to a decline in memory scores over time. Age was a significant confounder in all the analyses. The study had 80% power to detect a hazard ratio of 1.3 in the longitudinal analyses. Conclusion: High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time.

AB - Objective: To explore the association between high homocysteine levels and risk of Alzheimer disease (AD) in the Washington Heights-Inwood Columbia Aging Project (WHICAP). Methods: The authors obtained fasting plasma samples in 909 elderly subjects chosen at random from a cohort of Medicare recipients; there was longitudinal data in 679 subjects without dementia at baseline who were followed for 3,206 person-years. Prevalent and incident dementia and its subtypes were diagnosed using standard methods. Results: There were 128 persons with prevalent AD and 109 with incident AD in 3,206 person-years of follow-up. The adjusted OR of prevalent AD for the highest quartile of homocysteine compared to the lowest was 1.3 (95% CI = 0.7, 2.3; p for trend = 0.25). In longitudinal analyses, the authors found that the adjusted hazard ratio of AD for the highest quartile of homocysteine was 1.4 (95% CI = 0.8, 2.4; p for trend = 0.31). The authors also found that high homocysteine levels were not related to a decline in memory scores over time. Age was a significant confounder in all the analyses. The study had 80% power to detect a hazard ratio of 1.3 in the longitudinal analyses. Conclusion: High homocysteine levels were not associated with AD and were not related to a decrease in memory scores over time.

UR - http://www.scopus.com/inward/record.url?scp=2942538501&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942538501&partnerID=8YFLogxK

M3 - Article

C2 - 15184599

AN - SCOPUS:2942538501

VL - 62

SP - 1972

EP - 1976

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -